Featured Article

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.

Great Opportunity for Pharma People to Listen to What Doctors have to Say

An insightful and informative Q&A session with Dr. Tejal...

How Did Telma Become a 1000+ Cr Brand?

The untold story of Glenmark's phenomenal success in building...

Boehringer Ingelheim India focuses on partnerships in NCD management

Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Careers in Medical Device Companies

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Marketing

Careers in Medical Device Companies

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Policies/Sales

Careers in Medical Device Companies

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Strategy

Careers in Medical Device Companies

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Time for Indian Pharma to Dive into Digital

When was the first time that we heard the...

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Violence Against Doctors: Doctor-Patient Relationship Bruised and Battered

If a business fails, it was an idea that didn’t work. If treatment fails – it must be a botch up. A broken gadget may be beyond repair, but not a patient in a doctor’s hands. From such ungraded expectations stems the potential for things to take an ugly turn. An unwanted profession dealing with an unwanted condition, namely Ill health: If possible, we would wish away death and diseases, hospitals and doctors. A hospital is not a holiday resort, but it too costs money. And the scenario of an adverse outcome like death simply becomes unacceptable.